Supplemental data for:

Targeting MRTF/SRF in CAP2-dependent dilated cardiomyopathy

delays disease onset

Yao Xiong, Kenneth Bedi, Simon Berritt, Bennette K. Attipoe, Thomas Brooks, Kevin Wang, Kenneth B. Margulies and Jeffrey Field

## Supplementary figure legends

**Supplementary Figure 1** Gene expression and pathway changes in CAP2 KO hearts as determined by RNA-seq with differentially expressed genes chosen with FDR < 0.2 and fold change of at least 1.2 as indicated by the dashed lines. (A) Volcano plots of gene expression in CAP2 KO mice and CAP2 CKO mice. (B) SRF regulated genes are activated in CAP2 mutant hearts.

**Supplementary Figure 2** ECHO parameters in CAP2 KO mice. (A) Ejection fraction and Fractional shortening in CAP2 KO mice at 3 weeks old (n=6) and 13 weeks old (n=6) compared with age-matched controls (n=5~6). Data is presented as mean±SEM. P value compared with WT mice was determined using the 2-tailed paired t test.

**Supplementary Figure 3** SRF gene expression is activated by CAP loss in Hela cells. **(A)** CAP1, CAP2 and ACTA2 expression in CAP1 knockdown Hela cells. **(B)** Knock down of CAP2 in CAP1 knockdown Hela cells using siRNA stimulates ACTA2 expression. Data is presented as mean±SEM. P value compared with WT mice was determined using the 2-tailed paired t test. Three technical triplicates were used in each sample.

**Supplementary Figure 4** CAP2 loss does not activate SRF genes in fibroblasts and lack of significant fibrosis in CAP2 CKO hearts. (A) Expression of the indicated genes in CAP2 KO MEF cells. Data is presented as mean±SEM. P value compared with WT mice was determined using the 2-tailed paired t test. Three technical triplicates were used in each sample. (B) Sirius Red staining of mouse hearts.

**Supplementary Figure 5** Activation of SRF genes in CAP2 CKO mice. (A) Scheme for cardiac specific knockouts, CAP2 CKO mice. (B) Expression of CAP2 in the hearts from CAP2 CKO mice. (C) Expression of SRF genes in the hearts from CAP2 CKO mice. Data is presented as mean±SEM. P value compared with WT mice was determined using the 2-tailed paired t test. Three technical triplicates were used in each sample.

**Supplementary Figure 6** CCG-1423-8u inhibits translocation of MRTFA in MEF cells, determined by immune-staining.

**Supplementary Figure 7** Synthesis and characterization of the SRF inhibitor CCG-1423-8u. LRMS data was collected on a Waters Acquity UPLC equipped with SQD with electrospray ionization (ESI) in the positive mode. 1H NMR data was collected using a Bruker DRX 500 spectrometer at 500 MHz. The sample was dissolved in CDCl3.

Downregulated

Predicted activation

Predicted inhibition **Predicted Relationships** Leads to activation

Leads to inhibition **Findings inconsistent** 

molecule Effect not predicted

with state of downstream

confidence

 $\sim$ 

less



CSRP2

MYL1

MYOD1

\1/

EYA2

Nucleus

## Supplementary Figure 2

n=6





## Supplementary Figure 4



В











## Supplementary Figure 6

	DAPI	MRTFA	Merge
Control	4 F 8 8		
20% FBS	•		
GCG-1423-8u 1µM + 20% FBS	0 0 0 0	Pr C	



-Ó -1 ppm